Compare TNK & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNK | IMNM |
|---|---|---|
| Founded | 2007 | 2006 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.6B |
| IPO Year | 2007 | 2020 |
| Metric | TNK | IMNM |
|---|---|---|
| Price | $76.70 | $19.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $80.00 | $32.80 |
| AVG Volume (30 Days) | 343.3K | ★ 764.8K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.55% | N/A |
| EPS Growth | N/A | ★ 51.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,941,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,127.34 |
| P/E Ratio | $8.05 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $41.05 | $7.83 |
| 52 Week High | $83.99 | $27.65 |
| Indicator | TNK | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 47.98 | 31.70 |
| Support Level | $71.94 | $19.23 |
| Resistance Level | $80.97 | $23.24 |
| Average True Range (ATR) | 2.93 | 1.13 |
| MACD | -0.60 | -0.36 |
| Stochastic Oscillator | 16.73 | 0.00 |
Teekay Tankers Ltd is a provider of marine services to the international oil and natural gas industries and an operator of medium-sized oil tankers. The company operates in two segments: Tankers, which consists of the operation of all of the company's tankers (including the operations from those tankers employed on full service lightering contracts), and the company's U.S. based ship-to-ship support service operations (including its lightering support services provided as part of full service lightering operations); and Marine Services, which consists of operational and maintenance marine services provided to the Australian government, Australian energy companies and other third parties. The company generates the majority of its revenue from the Tankers segment.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.